Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Common Equity (2021 - 2025)

Senti Biosciences has reported Common Equity over the past 5 years, most recently at $5.6 million for Q4 2025.

  • For Q4 2025, Common Equity fell 78.21% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, down 78.21%, while the annual FY2025 figure was $5.6 million, 78.21% down from the prior year.
  • Common Equity for Q4 2025 was $5.6 million at Senti Biosciences, down from $8.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $154.3 million in Q2 2022 and troughed at -$121.8 million in Q1 2022.
  • A 5-year average of $24.8 million and a median of $31.8 million in 2024 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: skyrocketed 270.2% in 2022 and later tumbled 80.72% in 2024.
  • Year by year, Common Equity stood at -$111.5 million in 2021, then surged by 214.18% to $127.3 million in 2022, then crashed by 47.42% to $66.9 million in 2023, then tumbled by 61.67% to $25.6 million in 2024, then tumbled by 78.21% to $5.6 million in 2025.
  • Business Quant data shows Common Equity for SNTI at $5.6 million in Q4 2025, $8.1 million in Q3 2025, and $24.7 million in Q2 2025.